Markov model indicates cost-effectiveness of Cytosponge-TFF3 screening

The Cytosponge-TFF3 tandem for non-endoscopic screening is one of several being developed or newly available to expand screening for Barrett's or early stage adenocarcinoma at lower cost and with less invasiveness and patient inconvenience. In this report from the BEST3 Consortium, Markov modeling was used to investigate cost effectiveness and quality-adjusted life-years in a randomized clinical trial. They found an ICER of £5,500 (a relatively low amount), which might be even lower in a younger population.

EClinicalMedicine. 2021 Jun 18;37:100969. doi: 10.1016/j.eclinm.2021.100969. PMID: 34195582; PMCID: PMC8225801.

Economic evaluation of Cytosponge®-trefoil factor 3 for Barrett esophagus: A cost-utility analysis of randomised controlled trial data.

Swart N, Maroni R, Muldrew B, Sasieni P, Fitzgerald RC, Morris S; BEST3 Consortium.

Abstract

Background: Esophageal adenocarcinoma has a very poor prognosis unless detected early. The Cytosponge-trefoil factor 3 (TFF3) is a non-endoscopic test for Barrett esophagus, a precursor of esophageal adenocarcinoma. Randomised controlled trial data from the BEST3 trial has shown that an offer of Cytosponge-TFF3 in the primary care setting in England to individuals on medication for acid reflux increases detection of Barrett esophagus 10-fold over a year compared with standard care. This is an economic evaluation of Cytosponge-TFF3 screening versus usual care using data from the BEST3 trial which took place between 20th March 2017 and 21st March 2019.

Methods: A Markov model with a one-year cycle-length and a lifetime time horizon was created, adapting previous modeling work on Cytosponge screening. The impact of one round of Cytosponge screening was modelled in patients with a median age of 69 years (based on BEST3 trial population). Cost-effectiveness was expressed as an incremental cost-effectiveness ratio (ICER). Deterministic and probabilistic sensitivity analyses were conducted on model parameters.

Findings: Per person, one round of Cytosponge-TFF3 screening, including confirmatory endoscopy and treatment, in the intervention arm costed £82 more than usual care and generated an additional 0.015 quality-adjusted life-years (QALYs) at an ICER of £5,500 per QALY gained. Probabilistic sensitivity analysis gave an ICER of £5,405 (95% CI -£6,791 to £17,600). The average QALY gain per person is small because the majority of patients in the model will not develop BE and therefore will have no resulting change in their utility, however the small proportion of patients who are identified with BE dysplasia or cancer derive large benefit. At a willingness-to-pay threshold of £20,000 per QALY, the probability that Cytosponge-TFF3 was cost-effective was over 90%.

Interpretation: Using data from a pragmatic randomised trial, one-off Cytosponge-TFF3 screen is cost-effective relative to usual care for patients with gastro-esophageal reflux disease, despite relatively low uptake and an older population in this trial setting than previously modelled. Improving Cytosponge-TFF3 uptake and targeting younger patients is likely to further improve cost-effectiveness.

© 2021 The Authors.

About
This website contains a curated and opinionated look at recent literature regarding the epidemiology and prevention of esophageal cancer, with an emphasis on esophageal adenocarcinoma. It is developed by Thomas L Vaughan MD, MPH ©2021
Disclaimer
This website should not be considered, or used as a substitute for, medical advice, diagnosis or treatment. This site does not constitute the practice of any medical or other professional health care advice, diagnosis or treatment. The information on this website represent the views solely of Dr. Vaughan.
Privacy
Cookies are used solely to quantify website use for resource planning. Complete IP addresses are not collected (i.e., 203.0.113.123 will be recorded as 203.0.113.??) Feel free to opt out of cookies using add-ins of your choice without affecting website function. No user information is collected by the risk calculator (IC-RISC).